Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Samsara chief accounting officer sells $87,466 in stock

Samsara chief accounting officer sells $87,466 in stock

Chief Accounting Officer Benjamin Louis Kirchhoff of Samsara Inc. divested 2,165 shares of the company's Class A Common Stock on October 15, 2026. The sale, executed through a Rule 10b5-1 trading plan Kirchhoff established on September 30, 2025, occurred at a price of $40.4 per share, resulting in a total transaction value of $87,466.

Despite Samsara's stock surging 29% over the last six months, it currently trades at $39.57, slightly below Kirchhoff's sale price. As of the transaction, Kirchhoff still holds 148,921 shares directly beneficially owned in Samsara Inc. Class A Common Stock. Analysts' assessments of Samsara's valuation indicate the stock may be overpriced, placing it on the Most Overvalued list.

Samsara recently attracted attention from several analysts following a strong second-quarter performance. Guggenheim raised its price target to $51, maintaining a Buy rating, citing the company's robust revenue and annual recurring revenue (ARR). BNP Paribas Exane increased its price target to $55, also maintaining an Outperform rating, praising Samsara's impressive net new ARR growth.

Evercore ISI, too, raised its price target to $55, with an Outperform rating, citing the company's potential for sustained growth due to low market penetration. Cantor Fitzgerald initiated coverage with an overweight rating and a $45 price target, highlighting Samsara's long-term growth prospects.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.

  • Bristol-Myers Squibb reports $48.2 billion revenue in fiscal year 2025, down 0.2%.
  • Johnson & Johnson reports $94.2 billion revenue in fiscal year 2025, up 6%.
  • Johnson & Johnson has been a Dividend King for 64 consecutive years.

More from Saturday 17 October →